Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Registration Number
- NCT04855955
- Lead Sponsor
- Celltex Therapeutics Corporation
- Brief Summary
This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
- The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability.
- All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined
- Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy.
Exclusion Criteria
- Current diagnosis of malignancy
- Renal/liver dysfunction: Exceed two times as normal subject
- Pregnant or nursing
- Received other trial drugs within 30 days after participation of this study
- Experienced major surgery or trauma in the last 14 days
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method